Published in PLoS One on May 15, 2012
Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc Natl Acad Sci U S A (2014) 1.03
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem (2015) 1.00
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis (2015) 0.97
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol (2014) 0.96
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord (2014) 0.94
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging (2014) 0.87
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. Neuroscience (2014) 0.85
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis (2014) 0.84
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol Dis (2013) 0.83
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Front Genet (2014) 0.83
Non-motor and motor features in LRRK2 transgenic mice. PLoS One (2013) 0.81
LRRK2 mutations and neurotoxicant susceptibility. Exp Biol Med (Maywood) (2015) 0.79
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis (2014) 0.78
Dangerous duet: LRRK2 and α-synuclein jam at CMA. Nat Neurosci (2013) 0.78
LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease. Exp Neurobiol (2013) 0.78
Models of α-synuclein aggregation in Parkinson's disease. Acta Neuropathol Commun (2014) 0.77
Mouse Genetic Models of Human Brain Disorders. Front Genet (2016) 0.76
LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? Curr Neuropharmacol (2016) 0.76
LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes. Basal Ganglia (2013) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet (2011) 5.01
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet (2005) 3.63
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet (2011) 3.16
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
Biochemical and pathological characterization of Lrrk2. Ann Neurol (2006) 3.14
LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology (2007) 2.86
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) (2003) 2.75
LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci (2011) 2.52
Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet (2001) 2.52
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol (2011) 2.42
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Eur J Neurol (2008) 1.64
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord (2007) 1.56
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One (2010) 1.39
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci (2010) 1.35
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis (2010) 1.35
Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis (2010) 1.31
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci (2011) 1.25
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol Neurosurg Psychiatry (2007) 1.24
LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß. J Neurosci (2010) 1.23
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet (2009) 1.21
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci (2011) 1.13
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol (2007) 1.08
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A (2011) 1.05
Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet (2010) 1.03
LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal (2012) 1.02
Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal (2010) 1.01
Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord (2011) 1.01
Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci (2011) 0.98
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord (2010) 0.96
The role of common genetic risk variants in Parkinson disease. Clin Genet (2007) 0.96
Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol (2010) 0.96
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord (2009) 0.95
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov Disord (2007) 0.94
The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy. PLoS One (2010) 0.91
Neuropathology in mice expressing mouse alpha-synuclein. PLoS One (2011) 0.91
α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol Pharm Bull (2011) 0.90
Analysis of 39 Crohn's disease risk loci in Swedish inflammatory bowel disease patients. Inflamm Bowel Dis (2010) 0.89
Death in the substantia nigra: a motor tragedy. Expert Rev Neurother (2007) 0.81
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature (2005) 2.67
Synaptic inhibition in the olfactory bulb accelerates odor discrimination in mice. Neuron (2010) 2.40
Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem (2010) 2.10
Australopithecus sediba: a new species of Homo-like australopith from South Africa. Science (2010) 1.99
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol (2013) 1.96
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol (2006) 1.70
Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest (2011) 1.66
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Novel translational control in Arc-dependent long term potentiation consolidation in vivo. J Biol Chem (2009) 1.52
p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell (2009) 1.51
Occurrence of UV filters 4-methylbenzylidene camphor and octocrylene in fish from various Swiss rivers with inputs from wastewater treatment plants. Environ Sci Technol (2006) 1.47
Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain (2012) 1.42
Hexabromocyclododecane challenges scientists and regulators. Environ Sci Technol (2005) 1.42
Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem (2009) 1.42
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. J Biol Chem (2004) 1.38
Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. Am J Cardiol (2011) 1.38
Australopithecus sediba hand demonstrates mosaic evolution of locomotor and manipulative abilities. Science (2011) 1.37
Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. J Biol Chem (2003) 1.33
Biomarkers of depression in cancer patients. Cancer (2006) 1.32
A partial pelvis of Australopithecus sediba. Science (2011) 1.31
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol (2011) 1.31
Joint sealants: an overlooked diffuse source of polychlorinated biphenyls in buildings. Environ Sci Technol (2005) 1.30
Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther (2008) 1.28
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One (2012) 1.27
Targeted transgene expression in neuronal precursors: watching young neurons in the old brain. Eur J Neurosci (2006) 1.26
Three-dimensional fiber architecture of the nonpregnant human uterus determined ex vivo using magnetic resonance diffusion tensor imaging. Anat Rec A Discov Mol Cell Evol Biol (2006) 1.22
Endocrine activity and developmental toxicity of cosmetic UV filters--an update. Toxicology (2004) 1.18
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One (2012) 1.16
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer (2009) 1.15
ER-based double iCre fusion protein allows partial recombination in forebrain. Genesis (2002) 1.15
Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem (2002) 1.14
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol (2012) 1.13
A genetic switch for epilepsy in adult mice. J Neurosci (2004) 1.13
Anaerobic degradation of decabromodiphenyl ether. Environ Sci Technol (2005) 1.12
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol (2002) 1.09
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
Proteasome: an emerging target for cancer therapy. Anticancer Drugs (2005) 1.04
Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation (2009) 1.04
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
Uptake of water via branches helps timberline conifers refill embolized xylem in late winter. Plant Physiol (2014) 1.03
Frost drought in conifers at the alpine timberline: xylem dysfunction and adaptations. Ecology (2006) 1.02
Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal (2010) 1.01
A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J Biol Chem (2011) 0.98
Anaerobic degradation of brominated flame retardants in sewage sludge. Chemosphere (2006) 0.96
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res (2011) 0.96
Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol (2010) 0.96
A variant mimicking hyperphosphorylated 4E-BP inhibits protein synthesis in a sea urchin cell-free, cap-dependent translation system. PLoS One (2009) 0.95
Blast from the past: melting glaciers as a relevant source for persistent organic pollutants. Environ Sci Technol (2009) 0.94
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol (2007) 0.94
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med (2014) 0.94
Seclusion and restraint in patients with schizophrenia: clinical and biographical correlates. J Nerv Ment Dis (2007) 0.94
Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc Res Tech (2005) 0.94
Development of a method for the high-throughput quantification of cellular proteins. Chembiochem (2009) 0.93
Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health (2013) 0.92
Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med (2006) 0.92
Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach. Proteomics (2009) 0.92
The upper limb of Australopithecus sediba. Science (2013) 0.92
Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle. Fertil Steril (2002) 0.91
The cellular protein level of parkin is regulated by its ubiquitin-like domain. J Biol Chem (2003) 0.91
Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals. Eur J Pharmacol (2006) 0.91
The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy. PLoS One (2010) 0.91
Inhibitory activity of myelin-associated glycoprotein on sensory neurons is largely independent of NgR1 and NgR2 and resides within Ig-Like domains 4 and 5. PLoS One (2009) 0.91
Neuropathology in mice expressing mouse alpha-synuclein. PLoS One (2011) 0.91
Secondary effects of catalytic diesel particulate filters: conversion of PAHs versus formation of nitro-PAHs. Environ Sci Technol (2008) 0.90
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis (2003) 0.90
Part I: parkin-associated proteins and Parkinson's disease. Neuropharmacology (2003) 0.89
Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report. Cardiovasc Diabetol (2011) 0.89
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res (2009) 0.89
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hum Mol Genet (2012) 0.89
Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα) are both transcriptional regulators of the Runx2-I isoform. Mol Cell Endocrinol (2013) 0.89
Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: a randomized trial. Arch Phys Med Rehabil (2011) 0.88
Transgenic expression of intraneuronal Aβ42 but not Aβ40 leads to cellular Aβ lesions, degeneration, and functional impairment without typical Alzheimer's disease pathology. J Neurosci (2012) 0.87
Successful interventions on an organisational level to reduce violence and coercive interventions in in-patients with adjustment disorders and personality disorders. Clin Pract Epidemiol Ment Health (2008) 0.87
Impact of low- and high-oxidation diesel particulate filters on genotoxic exhaust constituents. Environ Sci Technol (2010) 0.87
The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci (2011) 0.86